Clinical trials: Gut Motility
Constipation
Probiotics for Alleviating Chronic Constipation in Adults
To investigate the clinical effects of probiotics in relieving intestinal motility and chronic constipation through regulating gut microbiota.
- Trial name
- NCT07152795
- Testing
- Probiotic
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Con, Cons ti
Probiotic for Alleviating Functional Constipation in Adults
To investigate the clinical effects of probiotics in relieving chronic constipation in adults, and evaluate the improvement of symptoms in patients with constipation as well as their impacts on gastrointestinal function and gut…
- Conditions
- Con, Cons ti, Con s ti
- Trial name
- NCT07649564
- Testing
- Probiotic
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Gastroesophageal Reflux Disease (GERD), Peptic Ulcers
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00261300
- Testing
- Pantoprazole
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Takeda
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Gastroparesis
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
This is a multi-center, parallel group, placebo-controlled and active-compared, randomized study to assess the ability of GSK962040 to enhance the delivery of enteral feed to critically ill subjects that are predisposed to…
- Trial name
- NCT01934192
- Testing
- GSK962040 50 mg, Metoclopramide 10 mg
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlaxoSmithKline
Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
Researchers want to learn more about the day-to-day use of Iberogast in people who have functional and motility-related gastrointestinal (stomach and bowel) diseases.
- Trial name
- NCT04993989
- Testing
- Iberogast (STW5, BAY98-7411)
- Where
- Germany
- Volunteers
- 843 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Gastric Acid Suppression, Proton Pump Inhibitors
Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium
This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in…
- Trial name
- NCT01130935
- Where
- 14 sites in Albania
- Volunteers
- 491 people
- Sponsor
- AstraZeneca
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 007)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
- Trial name
- ULISES (NCT01285570)
- Testing
- Ulimorelin Intravenously (IV), 5% dextrose in water
- Where
- 45 sites in United States, Hungary and 5 more
- Volunteers
- 332 people
- Sponsor
- Tranzyme, Inc.
Ileus
Neurostimulation for the Treatment of Post-Operative Ileus
The primary goal of this study is to validate the design of the ElectroCore RMS-1100 Resolution Motility System™ and the ability to safely place a stimulation electrode in the epidural space of the spine in a post-operative…
- Trial name
- NCT00854074
- Testing
- ElectroCore RMS-1100 Resolution Motility System™
- Where
- 3 sites in United States
- Sponsor
- ElectroCore INC
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 008)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
- Trial name
- NCT01296620
- Testing
- Ulimorelin Intravenously (IV), Ulimorelin Invtravenously (IV), 5% dextrose in water
- Where
- 50 sites in United States, Bulgaria and 4 more
- Volunteers
- 330 people
- Sponsor
- Tranzyme, Inc.
Reflux Esophagitis
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
- Trial name
- NCT04531475
- Testing
- X842, Lansoprazole
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastroesophageal Reflux, Gastric Ulcer
Safety of Rabeprazole in Patients Under Multiple Treatments
The purpose of this study is to evaluate the safety of rabeprazole 20mg/day in polymedicated patients and to examine the necessity of adjusted dosage in both therapies (rabeprazole and concomitant drug).
- Trial name
- NCT00511745
- Testing
- Rabeprazol
- Volunteers
- 2,157 people
- Sponsor
- Janssen-Cilag, S.A.
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Patients With Upper Gastro-intestinal Symptoms
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt
The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.
- Trial name
- GERD Q NIS (NCT01635959)
- Where
- 21 sites in Egypt
- Volunteers
- 3,170 people
- Sponsor
- AstraZeneca
Functional Gastrointestinal Disorders
Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function
Several studies have been done on the efficacy of the herbal medicine Iberogast. In this study researcher want to learn more about the time needed for Iberogast to start to work after the patient took the drug.
- Trial name
- NCT04059783
- Testing
- STW5 (Iberogast®, BAY98-7411)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Bayer
Gastroparesis
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and…
- Trial name
- NCT01039805
- Testing
- GSK962040 (50 mg), GSK962040 (75 mg)
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline